Previous Close | 1.1000 |
Open | 1.1000 |
Bid | 0.0000 x 800 |
Ask | 0.0000 x 800 |
Day's Range | 1.0700 - 1.1000 |
52 Week Range | 0.4000 - 10.9000 |
Volume | |
Avg. Volume | 11,074 |
Market Cap | 3.363M |
Beta (5Y Monthly) | 2.73 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -8.8800 |
Earnings Date | Mar 29, 2024 - Apr 02, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 30.00 |
Subscribe to Yahoo Finance Plus to view Fair Value for ELOX
Almirall obtains exclusive global rights to develop and commercialize ZKN-013 for the treatment of rare dermatological and other diseases associated with nonsense mutationsZKN-013 is a phase I ready oral therapy designed to overcome nonsense mutations that cause a premature stop codon resulting in nonfunctional protein production for example in recessive Dystrophic Epidermolysis Bullosa (RDEB), Junctional Epidermolysis Bullosa (JEB) and familial adenomatous polyposis (FAP) BARCELONA, Spain and W
While getting kicked off an exchange typically signals about the biggest warning sign you can possibly receive, a (somewhat) rational argument exists for delisted stocks to buy. Psychologically, companies go through much anxiety doing whatever they can to stay listed in a major exchange. Once booted, a certain clarity may materialize, leading to a recovery performance. In some sense, delisted enterprises represent the bears biggest nightmare because such organizations don’t have “anything” to lo
Kidney morphology improved in all three patients with protein re-expression consistent with disease regression in its Phase 2 open-label clinical trial of ELX-02 for the treatment of Alport Syndrome ELX-02 improved podocyte foot process effacement in all three treated patients by an average of 60% based on blinded biopsy analysis by NIPOKA GmbH Clinical data from Phase 2 study of ELX-02 for Alport Syndrome included in presentations at the American Society of Nephrology (ASN) Kidney Week 2023 Sig